Meta analysis using the most serious outcome reported shows 66% [52‑76%] and 86% [75‑92%] improvement for early treatment and prophylaxis
Statistically significant improvements are seen mortality, ventilatio, ICU admission, hospitalization, recovery, cases, and viral clearance. 30 studies show statistically significant improvements in isolation.
Results are very robust — in worst case exclusion sensitivity analysis 52 of 63 studies must be excluded to avoid finding statistically significant efficacy.
Over 20 countries have adopted ivermectin for COVID-19. The evidence base is much larger and has much lower conflict of interest than typically used to approve drugs.